Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

Jeffrey F. Ohren(Pfizer (United States)), Huifen Chen(Pfizer (United States)), A.G. Pavlovsky(Pfizer (United States)), Christopher E. Whitehead(Pfizer (United States)), Erli Zhang(Pfizer (United States)), Peter Kuffa(AstraZeneca (United States)), Chunhong Yan(Pfizer (United States)), Patrick McConnell(Pfizer (United States)), Cindy Spessard(Pfizer (United States)), Craig Banotai(Pfizer (United States)), W. Thomas Mueller(Pfizer (United States)), Amy M. Delaney(Pfizer (United States)), Charles A. Omer(University of Michigan–Ann Arbor), Judith S. Sebolt–Leopold(Pfizer (United States)), David T. Dudley(Pfizer (United States)), Iris Leung(Pfizer (United States)), Cathlin Flamme(Pfizer (United States)), Joseph S. Warmus(Pfizer (United States)), Michael D. Kaufman(Pfizer (United States)), Stephen D. Barrett(Pfizer (United States)), Haile Tecle(Pfizer (United States)), Charles A. Hasemann(Pfizer (United States))
Nature Structural & Molecular Biology
November 14, 2004
Cited by 619

Abstract


Related Papers

No related papers found

Powered by citation graph analysis